ASH Presentations 2022

Stanford BMT-CT ASH Abstracts 2022: Oral Abstracts

265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Caspian Oliai, MD, MS¹, Rasmus T Hoeg, MD^2*, Anna Pavlova, MD, PhD^3*, Arpita Gandhi, MD⁴, Lori Muffly, MD⁵, Rohtesh S. Mehta, MD⁶, Samer A Srour, MD, MS⁷, Edmund K. Waller, MD, PhD⁸, Robert Lowsky, MD⁹, Sagar S. Patel, MD¹⁰, Bhagirathbhai Dholaria, MBBS¹¹, Carlos Bachier, MD¹², Jeremy M. Pantin, MD, FACP¹³, Amandeep Salhotra, MD¹⁴, Joseph P. McGuirk, DO¹⁵, Nathaniel B Fernhoff, PhD^16*, J Scott McClellan, MD, PhD¹⁶, Mehrdad Abedi, MD², Robert S. Negrin, MD⁹ and Everett H Meyer, MD, PhD^9*https://ash.confex.com/ash/2022/webprogram/Paper165654.html

640 Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA
Hitomi Hosoya, MD, PhD¹, Mia Carleton^2*, Kailee L Tanaka^2*, Brian Sworder, MD, PhD³, Vanna Hovanky⁴^*, George E Duran, BA^2*, Tian Y. Zhang, MD, PhD⁵, Michael S. Khodadoust, MD PhD², David B. Miklos, MD, PhD⁴, Sally Arai, MD⁶, David Iberri, MD², Michaela Liedtke, MD², Surbhi Sidana, MD⁷ and David M. Kurtz, MD, PhD¹https://ash.confex.com/ash/2022/webprogram/Paper160370.html

982 CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
Nikeshan Jeyakumar, MD¹, Sneha Ramakrishna, MD², Matthew J Frank, MD, PhD³, Bita Sahaf, PhD⁴^*, Steven A. Feldman, PhD^4*, David B. Miklos, MD, PhD⁵, Crystal L. Mackall, MD⁶, Kara L. Davis, D.O.⁷, Lori Muffly, MD, MS⁸ and Liora M. Schultz, MD⁹https://ash.confex.com/ash/2022/webprogram/Paper164456.html

543 Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
Brian Sworder, MD, PhD¹, David M. Kurtz, MD, PhD¹, Stefan K. Alig, MD², Matthew J Frank, MD, PhD³, Navika D. Shukla, MD^4*, Andrea Garofalo^5*, Charles Macaulay, MSc, BA^5*, Mohammad Shahrokh Esfahani, PhD^2*, Mari Olsen^2*, James Hamilton III^6*, Hitomi Hosoya, MD, PhD⁶, Mark P Hamilton, MD⁷, Jay Y. Spiegel, MD, FRCPC⁸, John H. Baird, MD⁸, Mia Carleton^2*, Alexander F. M. Craig, MD, MPhil⁹, Sheren F. Younes, MD, PhD^10*, Bita Sahaf, PhD⁸^*, Natasha Sheybani, PhD^1*, Joseph Schroers-Martin, MD⁶, Chih Long Liu, PhD^6*, Jean S Oak, MD, PhD^10*, Michael C. Jin^6*, Sara Beygi, MD¹¹, Andreas Hüttmann, MD¹², Christine Hanoun^13*, Ulrich Dührsen, Prof, MD, PhD^13*, Jason Westin, MD¹⁴, Michael S. Khodadoust, MD PhD¹⁵, Yasodha Natkunam, MD, PhD¹⁶, Robbie G. Majzner, MD¹⁷, Crystal L. Mackall, MD^18,19, Maximilian Diehn, MD, PhD^20*, David B. Miklos, MD, PhD⁸ and Ash A. Alizadeh, MD, PhD²¹https://ash.confex.com/ash/2022/webprogram/Paper165545.html

720 Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Emily C. Liang, MD¹, Simone E. Dekker, MD, PhD², Jean M.G. Sabile, MD³, Stefan Torelli, MD^4*, Amy Zhang, MPH^5*, Katharine Miller, PhD^5*, Parveen Shiraz, MD⁶, Brandon Hayes-Lattin, MD⁷, Jessica Leonard, MD⁷ and Lori Muffly, MD⁶https://ash.confex.com/ash/2022/webprogram/Paper157442.html

994 Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Lori Muffly, MD, MS¹, Ariadna Garcia^2*, Katharine Miller, PhD^2*, Theresa H.M. Keegan, PhD³ and Helen Parsons, PhD MPH^4*https://ash.confex.com/ash/2022/webprogram/Paper163840.html

110 Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals
Lu Cui^1*, Cristabelle De Souza, Ph.D.^1*, Tristan Lerbs^1*, Jessica Poyser¹^*, Clarissa Yu^2*, Kerri Rieger, MD PhD^3*, Sally Arai, MD⁴, Ryanne Brown^5*, Judith A Shizuru, MD, PhD⁶, Antonia Maria Susanne Müller^7* and Gerlinde Wernig, MD⁸https://ash.confex.com/ash/2022/webprogram/Paper169789.html

765 Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
Matthew A. Lunning, DO, FACP¹, Hai-Lin Wang, MPH^2*, Zhen-Huan Hu, MPH^2*, Frederick L. Locke, MD³, Tanya Siddiqi, MD⁴, Caron A. Jacobson, MD⁵, Sairah Ahmed, MD⁶, David B. Miklos, MD, PhD⁷, Yi Lin, MD, PhD⁸, Brian T. Hill, MD, PhD⁹, Armin Ghobadi, MD¹⁰, Sattva S. Neelapu, MD¹¹, Jason Westin, MD¹², Harry Miao, MD, PhD^2*, Shilpa Shahani, MD^2*, Anik R. Patel, PhD^2*, Clare Spooner, MBBS, BSc^2*, Christine Fu, PhD^2*, Hairong Xu, MD, PhD^2* and Marcelo C Pasquini, MD, MS¹³

659 Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
Armin Ghobadi, MD¹, Javier Munoz, MD, MS, MBA², Jason Westin, MD³, Frederick L. Locke, MD⁴, David B. Miklos, MD, PhD⁵, Aaron P. Rapoport, MD⁶, Miguel-Angel Perales, MD⁷, Patrick M. Reagan, MD⁸, Joseph P. McGuirk, DO⁹, Caron A. Jacobson, MD¹⁰, Marie José Kersten, MD, PhD¹¹, Irit Avivi, MD^12*, Andrew Peng, MS^13*, Marco Schupp, MD^13*, Christina To, MD^13* and Olalekan O. Oluwole, MBBS¹⁴https://ash.confex.com/ash/2022/webprogram/Paper158303.html

766 Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
Christopher J. Ferreri, MD¹, Michelle A.T. Hildebrandt, PhD¹, Hamza Hashmi, MD², Leyla O. Shune, MD³, Joseph P. McGuirk, DO⁴, Douglas W. Sborov, MD⁵, Charlotte B Wagner, PharmD^6*, M. Hakan Kocoglu, MD⁷, Shebli Atrash, MD⁸, Peter M. Voorhees, MD⁹, Jack Khouri, MD¹⁰, Danai Dima, MD¹⁰, Aimaz Afrough, MD¹¹, Aishwarya Sannareddy, MBBS^12*, Gary Simmons, DO¹³, James Davis, PharmD^2*, Nilesh Kalariya^1*, Lauren C. Peres, PhD, MPH^14*, Melissa Alsina, MD**¹⁵, Frederick L. Locke, MD¹⁶, Surbhi Sidana, MD¹⁷, Doris K. Hansen, MD¹⁸, Krina Patel, MD, MSc¹⁹ and Omar Alexis Castaneda Puglianini, MD²⁰https://ash.confex.com/ash/2022/webprogram/Paper164884.html

252 Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
Lauren C. Peres, PhD, MPH^1*, Laura B. Oswald, PhD^2*, Christen Dillard, MD³, Gabriel De Avila, BS^4*, Taiga Nishihori, MD⁵, Brandon J. Blue, MD⁶, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP⁴, Frederick L. Locke, MD⁷, Melissa Alsina, MD**⁸, Omar Alexis Castaneda Puglianini, MD⁹, Leyla O. Shune, MD¹⁰, Douglas W. Sborov, MD¹¹, Charlotte B Wagner, PharmD^12*, Danai Dima, MD¹³, Hamza Hashmi, MD¹⁴, James Davis, PharmD^14*, M. Hakan Kocoglu, MD¹⁵, Shebli Atrash, MD¹⁶, Gary Simmons, DO¹⁷, Nilesh Kalariya^3*, Christopher J. Ferreri, MD³, Aishwarya Sannareddy, MBBS^18*, Aimaz Afrough, MD¹⁹, Peter M. Voorhees, MD²⁰, Jack Khouri, MD²¹, Joseph P. McGuirk, DO²², Surbhi Sidana, MD²³, Doris K. Hansen, MD⁵ and Krina Patel, MD, MSc²⁴https://ash.confex.com/ash/2022/webprogram/Paper158478.html

476 Microbial Bile Acid Metabolism Shapes Effector T Cell Responses during Inflammation in Mouse and Human
Sarah Lindner, MD^1*, Oriana Miltiadous, MD^2*, Ruben J Ramos^3*, Anqi Dai, MS^1*, Anastasia Kousa, PhD^1*, Gabriel K Armijo^1*, Romina Ghale^1*, Chi L Nguyen^1*, Jenny Paredes Sanchez, PhD^1*, Teng Fei, PhD^4*, John W Frame V^5*, Sebastien Monette, DMV, MVSc^6*, Emily Fontana^1*, John Slingerland^7*, Ying Taur, MD, MHP^5*, Marina D Burgos da Silva, PhD^1*, Kate A Markey, MBBS, M Clin Res, PhD, FRACP⁸, Jonathan U Peled, MD, PhD⁹, Melody Smith, MD, MS¹⁰, Sergio A Giralt, MD⁹, Miguel-Angel Perales, MD¹¹, Justin R Cross, PhD^3*, Clarissa Campbell, PhD^12* and Marcel R M van den Brink, MD, PhD¹¹https://ash.confex.com/ash/2022/webprogram/Paper167809.html

769 Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
Amandeep Salhotra, MD¹, Samer A Srour, MD, MS², Rasmus T Hoeg, MD^3*, Ayman Saad, MB/BCH^4*, Everett H Meyer, MD, PhD^5*, Anna Pavlova, MD, PhD⁶^*, Edmund K. Waller, MD, PhD⁷, Mwe Mwe Chao, MD^8*, J Scott McClellan, MD, PhD⁸, Nathaniel B Fernhoff, PhD^8*, Robert Lowsky, MD⁵ and Mehrdad Abedi, MD⁹https://ash.confex.com/ash/2022/webprogram/Paper170459.html

Stanford BMT-CT ASH Abstracts 2022: Poster Abstracts

4657 Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Sushma Bharadwaj, MD, MS^1*, Mark P Hamilton, MD², Bita Sahaf, PhD³^*, John Tamaresis, PhD⁴^*, Sunita Patil^5*, Paul J Hanson, PhD⁶^*, Theresa Latchford, RN^3*, Sally Arai, MD⁷, Laura J. Johnston, MD⁸, Robert Lowsky, MD⁸, Robert S. Negrin, MD⁸, Andrew R. Rezvani, MD⁹, Judith A Shizuru, MD, PhD¹, Everett H Meyer, MD, PhD^8*, Parveen Shiraz, MD⁸, Surbhi Sidana, MD¹⁰, Melody Smith, MD, MS¹¹, Wen-Kai Weng, MD, PhD¹², Lori Muffly, MD¹, Crystal L. Mackall, MD¹³, Matthew J Frank, MD, PhD¹⁴, David B. Miklos, MD, PhD⁸ and Saurabh Dahiya, MD¹⁵https://ash.confex.com/ash/2022/webprogram/Paper170759.html

4659 Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Surbhi Sidana, MD¹, Lauren C. Peres, PhD, MPH^2*, Hamza Hashmi, MD³, Hitomi Hosoya, MD, PhD⁴, Christopher J. Ferreri, MD⁵, Shebli Atrash, MD⁶, Jack Khouri, MD⁷, Peter M. Voorhees, MD⁶, Danai Dima, MD⁸, Gary Simmons, DO⁹, Nilesh Kalariya^5*, Vanna Hovanky^10*, Sushma Bharadwaj, MD, MS^11*, Sally Arai, MD¹², David B. Miklos, MD, PhD¹¹, Charlotte B Wagner, PharmD^13*, James Davis, PharmD^3*, Douglas W. Sborov, MD¹⁴, Taiga Nishihori, MD¹⁵, Melissa Alsina, MD**¹⁶, Frederick L. Locke, MD¹⁷, Rebecca Gonzalez, PharmD, BCOP^17*, M. Hakan Kocoglu, MD¹⁸, Aishwarya Sannareddy, MBBS^19*, Aimaz Afrough, MD²⁰, Joseph P. McGuirk, DO²¹, Leyla O. Shune, MD²¹, Krina Patel, MD, MSc²² and Doris K. Hansen, MD¹⁵https://ash.confex.com/ash/2022/webprogram/Paper166058.html

2106 Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Shona Philip, MD¹, Robert Lowsky, MD¹, Laura J. Johnston, MD¹, Sally Arai, MD², Everett H Meyer, MD, PhD^1*, Robert S. Negrin, MD¹, Andrew R. Rezvani, MD³, Parveen Shiraz, MD¹, Judith A Shizuru, MD, PhD⁴, Surbhi Sidana, MD⁵, Wen-Kai Weng, MD, PhD⁶, Sushma Bharadwaj, MD, MS^4*, Matthew J Frank, MD, PhD⁷, David B. Miklos, MD, PhD¹, Melody Smith, MD, MS⁸, Lori Muffly, MD⁴ and Vaibhav Agrawal, MD⁹https://ash.confex.com/ash/2022/webprogram/Paper168546.html

2090 Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Michelle Chin, MS¹, Judith A Shizuru, MD, PhD², Lori Muffly, MD², Parveen Shiraz, MD³, Laura J. Johnston, MD³, Robert Lowsky, MD³, Andrew R. Rezvani, MD³, Matthew J Frank, MD, PhD⁴, Sushma Bharadwaj, MD, MS^2*, Wen-Kai Weng, MD, PhD³, Robert S. Negrin, MD², David B. Miklos, MD, PhD² and Sally Arai, MD⁵https://ash.confex.com/ash/2022/webprogram/Paper165547.html

3358 Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Mark P Hamilton, MD^1,2,3, Felicia C Liu-Fei^3*, Stefan K. Alig, MD⁴, John Tamaresis, PhD^5*, Mohammad Shahrokh Esfahani, PhD^6*, Zinaida Good, PhD^3,5,⁷, Brian Sworder, MD, PhD⁸, Joseph Schroers-Martin, MD⁶, Chih Long Liu, PhD^6*, Freja Tang Severinsen, BSc^2,9*, Paul J Hanson, PhD³^*, Ying Lu, PhD^5*, Robert Lowsky, MD², Robert S. Negrin, MD², Everett H Meyer, MD, PhD^2*, Melody Smith, MD, MS², Sushma Bharadwaj, MD, MS^10*, Judith A Shizuru, MD, PhD^2,11, Surbhi Sidana, MD^2,3, Parveen Shiraz, MD², Andrew R. Rezvani, MD², Laura J. Johnston, MD², Wen-Kai Weng, MD, PhD², Sally Arai, MD¹², Lori Muffly, MD^2,3, Saurabh Dahiya, MD², Maximilian Diehn, MD, PhD^13*, David M. Kurtz, MD, PhD⁶, Bita Sahaf, PhD^3*, Crystal L. Mackall, MD^3,7,14, Matthew J Frank, MD, PhD¹⁵, David B. Miklos, MD, PhD^2,3 and Ash A. Alizadeh, MD, PhD^11,16https://ash.confex.com/ash/2022/webprogram/Paper165600.html

2849 Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS
Navika D. Shukla, MD^1*, Joseph Schroers-Martin, MD², Karan R. Kathuria^3*, Brian Sworder, MD, PhD⁴, Stefan K. Alig, MD³, Matthew J Frank, MD, PhD⁵, David B. Miklos, MD, PhD⁶, Steven Coutre, MD⁷, Maximilian Diehn, MD, PhD^8*, Michael S. Khodadoust, MD PhD³, Mark Roschewski, MD⁹, David M. Kurtz, MD, PhD¹⁰ and Ash A. Alizadeh, MD, PhD¹¹https://ash.confex.com/ash/2022/webprogram/Paper165656.html

2018 A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies
Sattva S. Neelapu, MD¹, Don A. Stevens, MD², Mehdi Hamadani, MD³, Matthew J Frank, MD, PhD⁴, Houston Holmes, MD, MBA^5*, Aya Jacobovits, PhD^6*, John Hinkle, PhD^7*, Jackie Kennedy-Wilde, MS^6*, Ori Maller, PhD^6*, Bayarmagnai Weinstein, MD, PhD^6*, Francesco Galimi, MD, PhD⁶, Rose K Lai, MD^6* and David B. Miklos, MD, PhD⁸https://ash.confex.com/ash/2022/webprogram/Paper157400.html

3345 Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel
Frederick L. Locke, MD¹, Zhen-Huan Hu, MPH^2*, Tanya Siddiqi, MD³, Caron A. Jacobson, MD⁴, Sarah Nikiforow, MD, PhD⁴, Sairah Ahmed, MD⁵, David B. Miklos, MD, PhD⁶, Yi Lin, MD, PhD⁷, Matthew A. Lunning, DO, FACP⁸, Brian T. Hill, MD, PhD⁹, Armin Ghobadi, MD¹⁰, Harry Miao, MD, PhD^2*, Shilpa Shahani, MD^2*, Clare Spooner, MBBS, BSc^2*, Christine Fu, PhD^2*, Anik R. Patel, PhD^2*, Hairong Xu, MD, PhD^2* and Marcelo C Pasquini, MD, MS¹¹https://ash.confex.com/ash/2022/webprogram/Paper155603.html

3866 Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
Jan Boegeholz, MD¹, Stefan K. Alig, MD², Brian Sworder, MD, PhD³, Joseph Schroers-Martin, MD⁴, Charles Macaulay, MSc, BA^5*, Alexander F. M. Craig, MD, MPhil⁶, Ulrich Duehrsen, MD⁷, Andreas Hüttmann, MD⁸, Jason Westin, MD⁹, Hua-Jay J. Cherng, MD¹⁰, David B. Miklos, MD, PhD¹¹, Matthew J Frank, MD, PhD¹², Maximilian Diehn, MD, PhD^13,14*, David M. Kurtz, MD, PhD⁴ and Ash A. Alizadeh, MD, PhD¹⁵https://ash.confex.com/ash/2022/webprogram/Paper170087.html

4628 Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Liora M. Schultz, MD¹, Sneha Ramakrishna, MD², Reema Baskar, PhD^3*, Rebecca M Richards, MD, PhD⁴, Jennifer Moon, jmoon@stanfordchildrens.org^5*, Christina Baggott, RN, PhD^6*, Michelle Fujimoto^7*, Michael Kunicki^5*, Amy Li, ali4@stanford.edu^8*, Sneha Jariwala^9*, Courtney Erickson^5*, Ashley Jacobs^9*, Karen Yamabe^10*, Valentin Barsan^10*, Robbie G. Majzner, MD¹¹, Emily L. Egeler, PhD^12*, Sharon Mavroukakis¹³^*, Zachary Ehlinger, MS^14*, Warren D. Reynolds, BS^14*, Bita Sahaf, PhD^12*, Lori Muffly, MD¹⁵, Matthew J Frank, MD, PhD¹⁶, Anne-Louise Gramstrup^17*, Harshini Chinnasamy, MS^12*, Shabnum Patel, PhD^3*, David B. Miklos, MD, PhD¹⁸, Steven A. Feldman, PhD^12*, Crystal L. Mackall, MD¹⁹ and Kara L. Davis, D.O.²⁰https://ash.confex.com/ash/2022/webprogram/Paper167789.html

4199 Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
Javier Munoz, MD, MS, MBA¹, Patrick M. Reagan, MD², Andre H. Goy, MD, MS^3*, David B. Miklos, MD, PhD⁴, Dan Zheng, PhD^5*, Xiang Fang, PhD^5*, Rhine R. Shen, PhD^5*, Rubina Siddiqi, PhD, MBA^5*, Ioana Kloos, MD, FRCPC^5*, Marie José Kersten, MD, PhD⁶ and Michael Wang, MD⁷https://ash.confex.com/ash/2022/webprogram/Paper158097.html

4677 Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
Jack Khouri, MD¹, Hong Li, MS^2*, Doris K. Hansen, MD³, Surbhi Sidana, MD⁴, Leyla O. Shune, MD⁵, Shaun DeJarnette^6*, Faiz Anwer, MD^1*, Douglas W Sborov^7*, Charlotte B Wagner, PharmD^7*, M. Hakan Kocoglu, MD⁸, Shebli Atrash, MD⁹, Peter M. Voorhees, MD¹⁰, Jason Valent, MD¹, Lauren C. Peres, PhD, MPH^11*, Vanna Hovanky^12*, Gary Simmons, DO¹³, Danai Dima, MD¹, Nilesh Kalariya^14*, Aimaz Afrough, MD¹⁵, Gurbakhash Kaur, MD^16*, Aishwarya Sannareddy, MBBS^17*, Christopher J. Ferreri, MD¹⁴, James Davis, PharmD^18*, Joseph P. McGuirk, DO¹⁹, Frederick L. Locke, MD²⁰, Rachid C. Baz, MD²¹, Betty K. Hamilton, MD²², Melissa Alsina, MD**²³, Craig S. Sauter, MD^24*, Hamza Hashmi, MD¹⁸ and Krina Patel, MD, MSc²⁵https://ash.confex.com/ash/2022/webprogram/Paper163464.html

2027 Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
Hamza Hashmi, MD¹, Doris K. Hansen, MD², Lauren C. Peres, PhD, MPH^3*, Omar Alexis Castaneda Puglianini, MD⁴, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP⁴, Gabriel De Avila, BS^4*, Surbhi Sidana, MD⁵, Leyla O. Shune, MD⁶, Douglas W. Sborov, MD⁷, James Davis, PharmD^1*, Charlotte B Wagner, PharmD^8*, M. Hakan Kocoglu, MD⁹, Shebli Atrash, MD¹⁰, Peter M. Voorhees, MD¹¹, Gary Simmons, DO¹², Christopher J. Ferreri, MD¹³, Nilesh Kalariya^13*, Aishwarya Sannareddy, MBBS^14*, Danai Dima, MD¹⁵, Jack Khouri, MD¹⁶, Joseph P. McGuirk, DO¹⁷, Frederick L. Locke, MD¹⁸, Rachid C. Baz, MD¹⁹, Krina Patel, MD, MSc²⁰ and Melissa Alsina, MD**²¹https://ash.confex.com/ash/2022/webprogram/Paper164828.html

2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Sham Mailankody, MBBS ¹, Jeffrey V. Matous, MD², Michaela Liedtke, MD³, Surbhi Sidana, MD⁴, Olalekan O. Oluwole, MBBS⁵, Meera Mohan, MD, MS^6*, Jose C. Cruz, MD⁷, Rajneesh Nath, MD⁸, Faiz Anwer, MD^9*, Adriana Rossi, MD, MSc¹⁰, Myo Htut, MD¹¹, Shahbaz A. Malik, MD¹², Srinivas Ghatta, PhD^13*, Myles Dillon, PhD^13*, Wendy Ying, PhD^13*, Lynn Navale, MS^13*, Erin E. Karski, MD^13*, Arun Balakumaran, MD¹³ and Shaji K Kumar, MD¹⁴https://ash.confex.com/ash/2022/webprogram/Paper158231.html

3414 Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
Sara J. Schonfeld, PhD^1*, Bryan Valcarcel, MD^1*, Christa L. Meyer, MS^2*, Ann M Brunson, MS^3*, Julianne J.P. Cooley, MS^4*, Renata Abrahao, MD, PhD, MSc³, Ted Wun, MD³, Jeffery Auletta, MD^2,5*, Lori Muffly, MD, MS⁶, Theresa H.M. Keegan, PhD³ and Lindsay M. Morton, PhD¹https://ash.confex.com/ash/2022/webprogram/Paper159010.html

3421 Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
Bryan Valcarcel, MD^1*, Sara J. Schonfeld, PhD^1*, Christa L. Meyer, MS^2*, Ann M Brunson, MS^3*, Julianne J.P. Cooley, MS^4*, Renata Abrahao, MD, PhD, MSc³, Ted Wun, MD³, Jeffery Auletta, MD^2,5*, Lori Muffly, MD, MS⁶, Theresa H.M. Keegan, PhD³ and Lindsay M. Morton, PhD¹https://ash.confex.com/ash/2022/webprogram/Paper160330.html

2275 Interim Update on the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies
Krish Patel, MD¹, Jakub Svoboda, MD², Bijal D. Shah, MD³, Bruce D. Cheson, MD⁴, Georges Azzi, MD^5*, Kashyap Patel, MD^6*, Andrew J Cowan, MD⁷, Lori Muffly, MD⁸, Heidi Simmons, PhD⁹, Mark Schliekelman, PhD^9* and Jessica Leonard, MD¹⁰https://ash.confex.com/ash/2022/webprogram/Paper167669.html

4520 Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
Naseem S Esteghamat, MD, MS¹, Ann M Brunson, MS^2*, Ted Wun, MD³, Aaron S Rosenberg, MD¹, Julianne J.P. Cooley, MS^4*, Sara J. Schonfeld, PhD^5*, Christa L. Meyer, MS^6*, Bryan Valcarcel, MD^5*, Renata Abrahao, MD, PhD, MSc⁷, Jeffery Auletta, MD^8,9, Lindsay M. Morton, PhD⁵, Lori Muffly, MD¹⁰ and Theresa H.M. Keegan, PhD⁷https://ash.confex.com/ash/2022/webprogram/Paper159776.html

3621 Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
Lori Muffly, MD, MS¹, Christopher Young, PhD^2*, Bin Xie, PhD^2*, Alana Block, PharmD^3*, Maelys Touya, PharmD^3* and Bhavik J. Pandya, PharmD^2*https://ash.confex.com/ash/2022/webprogram/Paper157964.html

3408 Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T
Everett H Meyer, MD, PhD^1*, M Scott Killian, PhD^2*, Anna Pavlova, MD, PhD^3*, Cameron Bader³^*, Sean Summers^2*, Fernando Teque^2*, J Scott McClellan, MD, PhD² and Nathaniel B Fernhoff, PhD^2*https://ash.confex.com/ash/2022/webprogram/Paper164468.html

4719 The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
Nahid Rashid, MD^1,2, Mukta Arora, MD³, Paul A. Carpenter, MD⁴, Amin M Alousi, MD⁵, Betty K. Hamilton, MD⁶, Joseph Pidala, MD, PhD⁷, Lynn E. Onstad, ScM^4*, Corey Cutler, MD, MPH, FRCPC⁸, Mary E. D. Flowers, MD¹, Sally Arai, MD⁹, Smita Bhatia, MD, MPH¹⁰ and Stephanie J. Lee, MD, MPH⁴https://ash.confex.com/ash/2022/webprogram/Paper167901.html

4767 Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
Shlomo Elias, MD, PhD^1*, Moneeza Walji, MD, BSc, MPH², Samantha Brown, MS^3*, Sean M. Devlin, PhD^4*, Esperanza B. Papadopoulos, MD^5,6, Ann A Jakubowski, MD PhD^5,6, Doris M. Ponce, MD^6,7, James W. Young, MD⁸, Sergio A Giralt, MD^9,10, Miguel-Angel Perales, MD^6,11, Brian C. Shaffer, MD^5,6, Parastoo B. Dahi, MD^6,12, Richard J. Lin, MD^6,11, Christina Cho, MD^5,6, Roni Tamari, MD^6,13, Melody Smith, MD, MS¹⁴^,15 and Boglarka Gyurkocza, MD^5,6https://ash.confex.com/ash/2022/webprogram/Paper170088.html

3335 A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Miguel-Angel Perales, MD¹, Sairah Ahmed, MD², Saurabh Dahiya, MD³, Peter A. Riedell, MD⁴, Joseph P. McGuirk, DO⁵, Olalekan O. Oluwole, MBBS⁶, Sohail A. Chaudhry, MD^7*, Zachary Lee, PharmD^7*, Stanley Dai^7*, Neha Dixit, PhD^7*, Christie Fanton, PhD^7*, Mario Q. Marcondes, MD, PhD⁷, Jonathan Zalevsky, PhD^7*, Mary A. Tagliaferri, MD^7* and Cameron J. Turtle, MBBS, PhD⁸https://ash.confex.com/ash/2022/webprogram/Paper162511.html

2032 Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Arushi Khurana, MBBS¹, Megumi Bailey, MSc^2*, Madiha Iqbal, MD³, Radhika Bansal, MBBS^1*, Catherine J. Lee, MD⁴, Bradley Hunter, MD, MPH⁵, Matthew A. Lunning, DO, FACP⁶, Samantha Jaglowski, MD, MPH⁷, Michael D. Jain, MD, PhD⁸, Saurabh Dahiya, MD⁹, Veronika Bachanova, MD, PhD¹⁰, Umar Farooq, MD¹¹, Sairah Ahmed, MD¹², Brian T. Hill, MD, PhD¹³, Javier L Munoz, MD, MBA^14*, Krish Patel, MD¹⁵, Olalekan O. Oluwole, MBBS¹⁶ and Yi Lin, MD, PhD¹⁷https://ash.confex.com/ash/2022/webprogram/Paper170486.html

4287 Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant
David Tong Chen, MD^1*, Olga Goloubeva, PhD, MSc^2*, Hanan Alkhaldi, MD^3*, Aaron P. Rapoport, MD³, Saurabh Dahiya, MD⁴, Nancy M. Hardy, MD³, Djordje Atanackovic, MD³, Mehmet Hakan Kocoglu, MD³, Forat Lutfi, MD³ and Jean A. Yared, MD⁵https://ash.confex.com/ash/2022/webprogram/Paper158281.html

2278 Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study
Brian J Scott, MD^1*, Tracy Murray, NP²^*, Gayle K Deutsch, PhD, ABPP^2*, Sheila Lahijani, MD^3*, Matthew J Frank, MD, PhD⁴ and Michelle Monje, MD, PHD^5*https://ash.confex.com/ash/2022/webprogram/Paper168229.html

2872 Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Tanaya Shree, MD, PhD¹, Sarah Haebe, MD^1*, Debra K. Czerwinski², Erik Eckhert, MD, MS³, Grady Day^1*, Anuja Sathe, MD, PhD^1*, Susan M. Grimes, BSc^4*, Matthew J Frank, MD, PhD⁵, Lauren S. Maeda, MD^6*, Ash A. Alizadeh, MD, PhD⁷, Ranjana H. Advani, MD⁸, Richard Hoppe, MD⁹, Steven R. Long, MD^10*, Brock Martin, MD^11*, Michael G. Ozawa, MD, PhD^11*, Michael S. Khodadoust, MD PhD¹², Hanlee P. Ji, MD^1* and Ronald Levy, MD¹https://ash.confex.com/ash/2022/webprogram/Paper167469.html

ASH SCIENTIFIC WORKSHOP

CAR T-Cells and the Gut Microbiome

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS
Scientific Workshops
Session: CAR T-cell Toxicities and Associations with Cytokine Profiling and the Gut Microbiome

Friday, December 9, 2022, 3:00 PM-4:00 PM

271-273 (Ernest N. Morial Convention Center)

Melody Smith, MD, MS

https://ash.confex.com/ash/2022/webprogram/Paper171531.html

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Intranet

News

Archive